Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par CEO replaced

Executive Summary

Patrick LePore takes over as president and CEO of Par Pharmaceutical following resignation of Scott Tariff at the request of the board of directors, the company announces Sept. 26. Executive chairman Mark Auerbach also steps down at board's request; former lead director John Abernathy will fill the role as non-executive chairman. LePore worked in sales and marketing at Roche from 1978 to 1984; in 2002, he oversaw the sale of medical communications company Boron LaPore & Associates to Cardinal Health. Par announced in July that it would be restating its financial results for 2004 through the first quarter of 2006, reducing Par's revenues over that time period by as much as $55 mil...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS047626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel